Table 1.

Clinicopathological characteristics of neuroendocrine carcinomas at the time of diagnosis (n = 43)

Median age (years)	66.0
Menopausal status
Premenopausal	2 (4.7%)
Postmenopausal	39 (90.7%)
Not confirmed	2 (4.7%)
T class
T1	29 (67.4%)
T2	11 (25.6%)
T3	2 (4.7%)
T4	1 (2.3%)
Mean size of primary tumor, mm (95% CI)	25.3 (18.9-31.7)
N class
N0	24 (55.8%)
N1	10 (23.3%)
N2	5 (11.6%)
N3	2 (4.7%)
Missing	2 (4.7%)
Mean number of lymph node metastases (95% CI)	2.2 (0.4-3.9)
Primary distant metastases
No	39 (90.7%)
Yes	4 (9.3%)
HER2 expression
Negative	40 (93.0%)
Positive	2 (4.7%)
Missing	1 (2.3%)
Estrogen receptor expression
Negative (0%)	1 (2.3%)
Low (1-9%)	0 (0%)
Moderate (10-59%)	0 (0%)
High (>60%)	41 (97.7%)
Missing	1 (2.3%)
Progesterone receptor expression
Negative (0%)	4 (9.3%)
Low (1-9%)	6 (14.0%)
Moderate (10-59%)	6 (14.0%)
High (>60%)	25 (58.1%)
Missing	2 (4.7%)
Ki-67 expression
Negative (<5%)	1 (2.3%)
Low (5-14%)	14 (32.6%)
Moderate (15-30%)	15 (34.9%)
High (>30%)	11 (25.6%)
Missing	2 (4.7%)
Multifocal disease
Yes	15 (35.9%)
No	28 (65.1%)
Synaptophysin expression
Yes	43 (100%)
No	0 (0%)
Chromogranin expression
Yes	30 (69.8%)
No	9 (20.9%)
Not available	4 (9.3%)